Knight Disposes of a Toddler-Sized Amount of Pediapharm Inc.
August 31 2018 - 5:31PM
This press release is being disseminated by Knight Therapeutics
Inc. ("Knight") (TSX:GUD), a specialty pharmaceutical company, as
required by National Instrument 62-103 - The Early Warning System
and Related Take Over Bid and Insider Reporting Issues regarding
the disposition of securities of Pediapharm Inc. ("Pediapharm").
Since July 4, 2018, Knight disposed of an
aggregate of 93,500 shares of Pediapharm ("Shares") on the TSX
Venture Exchange at an average price of $0.46 per share for total
gross proceeds of $43,130.
Knight’s early warning report of January 13,
2017 indicated ownership of 11,964,420 common shares of Pediapharm
and 757,500 warrants ("Warrants"), convertible into 757,500 common
shares of Pediapharm, representing 17.3% of the issued and
outstanding common shares of Pediapharm, assuming the exercise of
the Warrants held by Knight only. On July 4, 2017, Pediapharm
announced it closed a non-brokered private placement and issued
14,705,883 common shares. Immediately after the disposition
of the Shares, Knight held 11,193,920 common shares of Pediapharm
and the Warrants, representing 13.6% of the issued and outstanding
common shares of Pediapharm, assuming the exercise of the Warrants
held by Knight only.
Knight may in the future purchase or sell shares
of Pediapharm or otherwise trade in securities of or engage in
other transactions with respect to Pediapharm depending on a number
of factors, including but not limited to, Pediapharm's financial
position, the price levels of the common shares of Pediapharm,
conditions in the securities markets and general economic and
industry conditions, Pediapharm's business or financial condition,
and other factors and conditions Knight deems appropriate.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in
Montreal, Canada, is a specialty pharmaceutical company focused on
acquiring or in-licensing innovative pharmaceutical products for
the Canadian and select international markets. Knight Therapeutics
Inc.'s shares trade on TSX under the symbol GUD. For more
information about Knight Therapeutics Inc., please visit the
company's web site at www.gudknight.com or www.sedar.com.
Forward-Looking Statement
This document contains forward-looking
statements for Knight Therapeutics Inc. and its subsidiaries. These
forward-looking statements, by their nature, necessarily involve
risks and uncertainties that could cause actual results to differ
materially from those contemplated by the forward-looking
statements. Knight Therapeutics Inc. considers the assumptions on
which these forward-looking statements are based to be reasonable
at the time they were prepared, but cautions the reader that these
assumptions regarding future events, many of which are beyond the
control of Knight Therapeutics Inc. and its subsidiaries, may
ultimately prove to be incorrect. Factors and risks, which could
cause actual results to differ materially from current expectations
are discussed in Knight Therapeutics Inc.'s Annual Report and in
Knight Therapeutics Inc.'s Annual Information Form for the year
ended December 31, 2017. Knight Therapeutics Inc. disclaims any
intention or obligation to update or revise any forward-looking
statements whether as a result of new information or future events,
except as required by law.
CONTACT INFORMATION:
Knight Therapeutics Inc. Samira Sakhia President & Chief
Financial Officer T: 514-678-8930 F: 514-481-4116
info@gudknight.com www.gudknight.com
Knight Therapeutics (TSX:GUD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Knight Therapeutics (TSX:GUD)
Historical Stock Chart
From Sep 2023 to Sep 2024